Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Santarus Inc. (NASDAQ:SNTS) jumped $2.13 (11%) to $21 in early
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury